Holen Sie sich die Stockscreener-App
17.98
2.34%
-0.43
Handel nachbörslich:
18.00
0.02
+0.11%
Schlusskurs vom Vortag:
$18.41
Offen:
$17.89
24-Stunden-Volumen:
433.76K
Relative Volume:
1.15
Marktkapitalisierung:
$6.37B
Einnahmen:
$4.89B
Nettoeinkommen (Verlust:
$-263.00M
KGV:
-23.25
EPS:
-0.7734
Netto-Cashflow:
$-167.84M
1W Leistung:
-2.49%
1M Leistung:
+10.92%
6M Leistung:
+22.90%
1J Leistung:
+13.37%
1-Tages-Spanne:
$17.48
$18.22
1-Wochen-Bereich:
$17.48
$18.91
52-Wochen-Spanne:
$10.45
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.98 | 6.52B | 4.89B | -263.00M | -167.84M | -0.7734 |
|
ISRG
Intuitive Surgical Inc
|
497.42 | 176.23B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
174.21 | 50.22B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
83.08 | 41.28B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
258.28 | 37.50B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
44.39 | 37.20B | 27.43B | 1.27B | 1.01B | 1.5829 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Neutral |
| 2025-05-02 | Bestätigt | H.C. Wainwright | Buy |
| 2025-03-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Bausch & Lomb (NYSE: BLCO) SVP disposes shares for taxes - Stock Titan
Bausch & Lomb (BLCO) officer has shares withheld for RSU tax - Stock Titan
Tax-withholding share moves by Bausch & Lomb (NYSE: BLCO) executive - Stock Titan
Bausch & Lomb (BLCO) EVP uses share withholding to cover tax on RSU vesting - Stock Titan
Bausch & Lomb (BLCO) EVP uses shares for tax withholding on RSU vesting - Stock Titan
CFO tax share withholding at Bausch & Lomb (BLCO) after RSU vesting - Stock Titan
Bausch & Lomb (BLCO) CEO uses common shares to cover RSU tax - Stock Titan
BLCO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bausch & Lomb (BLCO) SVP awarded 18,253 restricted share units in Form 4 - Stock Titan
Executive at Bausch & Lomb (NYSE: BLCO) granted 32,710 restricted share units - Stock Titan
327,102-share RSU award to Bausch & Lomb (BLCO) CEO Brent Saunders - Stock Titan
Bausch + Lomb Corp. Hits New 52-Week High at $18.91 - Markets Mojo
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Bausch + Lomb (BLCO) Reports Record Q4 2025 Financial Results Driven by Strong Pharmaceutical and Vision Care Growth - Insider Monkey
BLCO Should I Buy - Intellectia AI
Bausch & Lomb (BLCO) CEO uses 65,444 shares to cover tax withholding - Stock Titan
Is Expert Backing Of LUMIFY’s Safety Profile Quietly Shaping Bausch + Lomb’s Consumer Strategy (BLCO)? - simplywall.st
Bausch + Lomb stock hits 52-week high at $18.86 - Investing.com
Global Ophthalmic Drugs Market Estimated at US$41.88 Billion in 2026; Projected to Grow at 7.9% CAGR Through 2036 - GlobeNewswire Inc.
5 Revealing Analyst Questions From Bausch + Lomb's Q4 Earnings Call - Finviz
Director Steven Collis adds BLCO stake with 15,000-share buy and RSU grant - Stock Titan
Director boosts Bausch & Lomb (BLCO) stake with share buy and matching RSUs - Stock Titan
Is It Time To Reassess Bausch + Lomb (BLCO) After Its Recent Share Price Strength? - Yahoo Finance
H.C. Wainwright raises Bausch & Lomb stock price target to $20 - Investing.com South Africa
Bausch + Lomb Corporation - Baystreet.ca
H.C. Wainwright raises Bausch & Lomb stock price target to $20 By Investing.com - Investing.com Canada
HC Wainwright Comments on Bausch + Lomb Q1 Earnings - MarketBeat
Digital lifestyles are turning eyes red – and one drop stands out - Stock Titan
Adding B Vitamins To AREDS Has Bausch + Lomb Seeing Consumer Health Sales Boost Ahead - Citeline News & Insights
Separation Overhang Continues to Weigh on Bausch Health Companies Inc. (BHC) Outlook - Insider Monkey
Director receives 5,255 RSUs at Bausch & Lomb (NYSE: BLCO) - Stock Titan
Bausch & Lomb (BLCO) awards 5,255 RSUs to director - Stock Titan
Director at Bausch & Lomb (BLCO) receives 1,451 restricted share units - Stock Titan
Director John Paulson granted 1,239 Bausch & Lomb (BLCO) restricted share units - Stock Titan
H.C. Wainwright Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Raises Target Price to $20 - 富途牛牛
Market Rankings: Is BSBK benefiting from innovation trendsJuly 2025 Volume & Consistent Profit Alerts - baoquankhu1.vn
Bausch & Lomb (NYSE: BLCO) EVP earns 29,406 performance-based shares - Stock Titan
Stifel raises Bausch & Lomb stock price target on strong Miebo sales - Investing.com South Africa
Bausch & Lomb (NYSE: BLCO) SVP earns 12,498-share performance award - Stock Titan
Deutsche Bank Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $18 - 富途牛牛
Bausch + Lomb price target raised to $15 from $13 at BofA - TipRanks
Breaking Down Bausch & Lomb: 6 Analysts Share Their Views - Benzinga
Bausch + Lomb price target raised to $21 from $20 at Citi - TipRanks
Bausch + Lomb (BLCO) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
BofA Securities Maintains Bausch + Lomb Corp.(BLCO.US) With Sell Rating, Maintains Target Price $15 - 富途牛牛
Bausch + Lomb Corporation (NYSE:BLCO) Q4 2025 Earnings Call Transcript - Insider Monkey
A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $15 to $21 - 富途牛牛
Needham Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating - 富途牛牛
Beyond the Balance Sheet: What SWOT Reveals About Bausch & Lomb Corp (BLCO) - GuruFocus
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.00%
0.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):